Meeting
2020 ASCO Virtual Scientific Program
APOLLO: A phase I study of adaptive memory natural killer (NK) cells in recurrent ovarian cancer.
Authors
Melissa Ann Geller
University of Minnesota, Minneapolis, MN
Melissa Ann Geller , Sarah A. Cooley , Mark Wallet , Bahram Valamehr , Deanna Gek Koon Teoh , Todd E. DeFor , Martin Felices , Jeffrey Miller
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT00652899
Citation
J Clin Oncol 38: 2020 (suppl; abstr 6044)
DOI
10.1200/JCO.2020.38.15_suppl.6044
Abstract #
6044
Poster Bd #
215
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1/1b study of PRGN-3005 autologous UltraCAR-T cells manufactured overnight for infusion next day to advanced stage platinum resistant ovarian cancer patients.
First Author: John B. Liao
Poster
2023 ASCO Annual Meeting
A phase 1 trial of umbilical cord blood–derived tumor-reactive PD-L1+ natural killer cells engineered to express soluble IL-15 (TRACK-NK) in patients with non–small-cell lung cancer (NSCLC) refractory to PD-1/PD-L1 inhibitors.
First Author: Miguel Angel Villalona-Calero
Poster
2022 ASCO Annual Meeting
Phase 2 Quilt 88 trial of DAMP inducers combined with IL15 superagonist, N-803, and anti–PD-L1 NK cell therapy more than doubles historical overall survival in patients with third- to sixth-line advanced pancreatic cancer.
First Author: Tara Elisabeth Seery
Poster
2021 ASCO Annual Meeting
An armored GPC3-directed CAR-T for refractory or relapsed hepatocellular carcinoma in China: A phase I trial.
First Author: Zhongwei Zhao